IL-2 and Histamine Treatment for Kidney Cancer
Author Information
Author(s): Donskov F, Middleton M, Fode K, Meldgaard P, Mansoor W, Lawrance J, Thatcher N, Nellemann H, von der Maase H
Primary Institution: Department of Oncology, Aarhus University Hospital
Hypothesis
Does adding histamine dihydrochloride to interleukin-2 improve treatment outcomes in patients with metastatic renal cell carcinoma?
Conclusion
The addition of histamine to interleukin-2 showed a significant survival benefit in the Danish study, while the UK study did not show any benefits.
Supporting Evidence
- The Danish study showed a statistically significant 1-year survival benefit (76% vs 47%).
- The UK study did not show any significant differences in treatment outcomes.
- Overall response rates were not statistically significantly different between treatment groups.
Takeaway
This study tested if a medicine called histamine could help another medicine, interleukin-2, work better for people with kidney cancer. It helped some patients live longer.
Methodology
Two parallel randomised phase II trials were conducted comparing IL-2 with or without histamine in patients with metastatic renal cell carcinoma.
Potential Biases
Differences in patient characteristics between the two study centers may introduce bias.
Limitations
The UK study did not show any benefits, and the outcomes of the two studies differed significantly.
Participant Demographics
Patients aged 18-75 with metastatic renal cell carcinoma, with a mix of male and female participants.
Statistical Information
P-Value
0.03
Confidence Interval
0.36–1.05
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website